Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More

Imunon, Inc. (NASDAQ:IMNN) has completed a private placement, securing $3.25 million in initial funding by selling 7,222,223 shares of common stock or pre-funded warrants at $0.45 each. The deal also grants investors short-term warrants to buy up to 14,444,446 additional shares at the same price. If all warrants are exercised within three years after shareholder approval, Imunon, Inc. (NASDAQ:IMNN) could raise an extra $6.5 million, bringing total potential proceeds to $9.75 million.

H.C. Wainwright & Co. led the transaction, with Brookline Capital Markets as co-placement agent. The funds are earmarked for working capital and general corporate needs. The securities, offered only to accredited investors under a private placement, are not registered with the SEC and cannot be resold publicly until registration is completed.

Imunon, Inc. (NASDAQ:IMNN) has agreed to file registration statements for future resale, and this announcement does not represent an offer or sale where prohibited by law.

While we acknowledge the potential of IMNN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than IMNN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.